Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Schibsted Media in connection with its acquisition of TV4 and MTV Finland
Mandate

Vinge advises Schibsted Media in connection with its acquisition of TV4 and MTV Finland

February 25, 2025 M&A Commercial Agreements Intellectual Property Data protection and processing of personal data Employment and Benefits Real Estate and Construction FDI EU, Competition and Regulatory Corporate Crime & Compliance Carve-Outs

Schibsted Media has entered into an agreement to acquire Telia Company’s TV & Media business, consisting of TV4 and MTV Finland. The transaction implies an enterprise value of SEK 6.55 billion on a cash and debt-free basis and it is expected to close in Q3 2025, subject to customary regulatory approvals.

Vinge’s team consisted mainly of Johan Larsson, Johan Winnerblad, Jesper Ottergren, Per Kling, Nathalie Wikman (M&A), Eva Fredrikson, Martin Boström, Elis Allmark,  Mario Saad (Commercial agreements), Malin Malm Waerme, Arvid Axelryd, Ian Jonson, Alva Skott, Melinda Oldenburg (Intellectual property), Nicklas Thorgerzon (GDPR), Sam Seddigh, Emil Lindwall, Agnes Pigg (Employment and benefits), Kristoffer Larson, Sara Franson (Real estate), Marcus Glader, Fredrik Hellström, Jakob Jeanrond, Martin Bergqvist, Martin Hammarskiöld (Competition and FDI), Martin Johansson, Carl Johan af Petersens, Hampus Peterson (Compliance and regulatory).

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026